Tristel PLC · LSE:TSTL

Tristel — H1 2015-16 Earnings Presentation

16 slides from Tristel's earnings presentation, Feb 24, 2016

  1. Slide 1: Interim results presentation 31 December 2015

    Slide 1: Interim results presentation 31 December 2015

    Paul Swinney: CEO Paul Swinney: CEO Liz Dixon: FD Liz Dixon: FD Interim results presentation 31 December 2015

  2. Slide 2: Financial Highlights

    Slide 2: Financial Highlights

    Financial Highlights • Revenue up 8% to £8m (2014: £7.4m) • Overseas sales up 20% to £2.9m (2014: £2.4m), representing 36% of total sales • EBITDA and share based payments up 27% to £1.9m (2014: £1.5m) • Pre-tax profit before share based payments up 36% to £1.5m (2014: £1.1m) • EPS before share base

  3. Slide 3: Operational Highlights

    Slide 3: Operational Highlights

    Operational Highlights • Focus on margins and cost control • Successful implementation of Enterprise Resource Planning system throughout the Group • Continued investment for future growth • 510(K) pre-submission meeting request made to the United States Food and Drug Administration (FDA) 3

  4. Slide 4: Lead technology

    Slide 4: Lead technology

    Lead technology Our proprietary chlorine dioxide formulation addresses three distinct markets: • The Human Healthcare market (hospital infection prevention – via the Tristel brand). • The Contamination Control market (control of contamination in critical environments – via the Crystel brand). • The

  5. Slide 5: Strategic financial goals

    Slide 5: Strategic financial goals

    Strategic financial goals £20m revenue by 30 June 2017 Maintain at least a 15% pre-tax profit margin 20% 18% 15% 13% +29% 10% 2013-14 H1 2013-14 H2 2014-15 H1 2014-15 H2 2015-16 H1 Gross profit 72% Gross profit 50% Net margin Unlikely to be achieved due to slowing UK growth o Current focus on margin

  6. Slide 6: Revenue dynamics

    Slide 6: Revenue dynamics

    Revenue dynamics £,000 2015-16 2014-15 Growth £,000 2015-16 2014-15 Growth Half 1 Half 1 Half 1 Half 1 Human 6,740 84% 6,332 86% 408 6% Germany 794 10% 665 9% 19% healthcare Animal 500 6% 397 5% 103 26 Australasia 491 6% 495 7% - healthcare % Contamination 770 10% 693 9% 77 11 Asia 486 6% 286 4% 70%

  7. Slide 7: Revenue detail

    Slide 7: Revenue detail

    Revenue detail £,000 2013-14 2014-15 2014-15 2015-16 UK H2 H1 H2 H1 Human healthcare Out-patient instrument disinfection 2,160 2,621 2,469 2,695 Critical surface disinfection 521 586 583 620 Other 949 1,023 950 840 Contamination control 499 518 469 589 Animal healthcare 319 258 356 373 4,448 5,006 4

  8. Slide 8: Productivity investments & gross margin improvements

    Slide 8: Productivity investments & gross margin improvements

    Productivity investments & gross margin improvements Gross margin 2015-16 2014-15 Margin Stock 31 December 31 December Stock holding Half 1 Half 1 improvement 2015 2014 reduction Human healthcare 74% 72% 2% Finished goods 826 901 75 Animal healthcare 69% 61% 2% Componentry 763 1,096 333 Contaminatio

  9. Slide 9: Selection of regulatory approval initiatives

    Slide 9: Selection of regulatory approval initiatives

    Selection of regulatory approval initiatives Product Stella Wipes/Duo Fuse/Jet/Duo Application Various Ultrasound Ophthalmology ENT Surfaces USA 0 1 1 0 0 Taiwan 1 1 1 1 1 Australia/NZ 4 3 1 3 2 South Korea 0 1 1 1 - Key - No plans to register Nigeria 1 1 1 1 1 0 Under consideration Peru 1 1 1 1 1 1

  10. Slide 10: USA regulatory approval initiative

    Slide 10: USA regulatory approval initiative

    USA regulatory approval initiative Approval body Progress Non regulated EPA FDA FDA & EPA Approval Approval feasibility proven programme underway Duo Ophthalmology * Y Y Duo Ultrasound * Y Y Filtershot Y To start Q4 15-16 Rinse Assure Y To start Q4 15-16 Stella Y Not yet decided Fuse for Stella Not

  11. Slide 11: Outlook and Summary

    Slide 11: Outlook and Summary

    Outlook and Summary • Revenues up 8% but below management target of 15% p.a. o long-term revenue growth expected from further geographical expansion and new products • Focus on margin improvement – inc. exit from certain low margin non-chlorine dioxide products • Margin, costs and cash tightly manag

  12. Slide 12: Income Statement

    Slide 12: Income Statement

    Income Statement Six months Six months ended ended 31.12.15 31.12.14 £’000 £’000 Turnover 8,010 7,412 Cost of sales (2,289) (2,301) Gross profit 5,721 5,111 Gross margin % 71% 69% Administrative expenses (3,850) (3,600) Net interest expense 4 3 Depreciation & amortisation (401) (422) Share based pay

  13. Slide 13: Balance Sheet

    Slide 13: Balance Sheet

    Balance Sheet 31.12.15 31.12.14 Non-current assets £,000 £’000 Goodwill 667 667 Intangible assets 5,586 5,593 Property, plant and equipment 1,330 1,319 Deferred tax 37 44 7,620 7,623 Current assets Inventories 1,589 1,997 Trade and other receivables 3,319 2,764 Cash and cash equivalents 4,264 2,945

  14. Slide 14: Balance Sheet continued

    Slide 14: Balance Sheet continued

    Balance Sheet continued 31.12.15 31.12.14 Capital and reserves £’000 £’000 Share capital 421 407 Share premium account 10,455 9,517 Merger reserve 478 478 Foreign exchange reserve (134) (101) Retained earnings 2,559 2,323 Minority interests 7 7 Total equity 13,786 12,631 Current liabilities Interest

  15. Slide 15: Cash flow reconciliation

    Slide 15: Cash flow reconciliation

    Cash flow reconciliation 31.12.15 31.12.14 £’000 £’000 Profit before tax 465 1,033 Add back non cash items 1,409 474 Working capital movements 357 (437) Purchase of fixed assets (203) (244) Purchase of intangible assets (147) (181) Proceeds from sale of property, plant & equipment 16 8 Shares issued

  16. Slide 16: Paulswinney@tristel.com lizdixon@tristel.com tristel@walbrook.com

    Slide 16: Paulswinney@tristel.com lizdixon@tristel.com tristel@walbrook.com

    16 Paulswinney@tristel.com lizdixon@tristel.com tristel@walbrook.com

Source: Internet Archive copy of tristel.com

More decks from Tristel PLC

All 32 Tristel decks